Pharmaceutical company · BHC

Bausch Health
clinical trial
pipeline

Registry checked

Published

Bausch Health's mapped programme view covers 13 of 23 active trials through accepted investigational links. The coverage does not establish a complete corporate drug portfolio. Rifaximin SSD is linked to 1 distinct active study, with 1 Phase 3. Brodalumab is linked to 1 distinct active study, with 1 Phase 4.

Phase 2 study NCT07778888 in Dry Eye Disease lists estimated primary completion in February 2027. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

23active trials
as lead sponsor
  • Phase 11
  • Phase 22
  • Phase 32
  • Phase 48
  • Phase not recorded10

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

30 Sept 2026 – 29 Oct 2026 · UTC

Recorded changes

146 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

03Primary completion

Primary completion moved later

2026-01 (estimated)2026-02-24 (actual)
Jan 202624 Feb 2026

Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

NCT05297448 · ClinicalTrials.gov
Recorded by ComplyRx
29 Oct 2026
Registry last updated
28 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-09-300000000
2026-10-010000000
2026-10-020000000
2026-10-032100032
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-070100011
2026-10-080000000
2026-10-091100021
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-160000000
2026-10-170000000
2026-10-180000000
2026-10-190000000
2026-10-200000000
2026-10-210000000
2026-10-220000000
2026-10-231110031
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-280000000
2026-10-291110251
Type totals55202146 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Brodalumab

siliq

1
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 30
  • Phase 41
  • Phase not recorded0
Studied condition
Psoriasis
Next primary completion
Not reported
Open drug

Budesonide

budesonideinhalation · budesonideinhalationsuspension · ENTOCORT EC · eohilia · Pulmicort Respules · pulmicortflexhaler

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 30
  • Phase 41
  • Phase not recorded0
Studied condition
Ulcerative Colitis
Next primary completion
Not reported
Open drug

Budesonide rectal foam

Canonical investigational asset

1
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 30
  • Phase 41
  • Phase not recorded0
Studied condition
Ulcerative Colitis
Next primary completion
Not reported
Open drug

Bupropion

APLENZIN · APLENZIN ER · AUVELITY · WELLBUTRIN SR

1
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 30
  • Phase 41
  • Phase not recorded0
Studied condition
Major Depressive Disorder
Next primary completion
Not reported
Open drug

Cabtreo (Clindamycin/Benzoyl Peroxide/Adapalene)

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 30
  • Phase 41
  • Phase not recorded0
Studied condition
Acne Vulgaris
Next primary completion
Not reported
Open drug

IDP-122 Lotion

Canonical investigational asset

1
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 30
  • Phase 41
  • Phase not recorded0
Studied condition
Psoriasis
Next primary completion
Not reported
Open drug

13 of 23 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 13 of 23 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Bausch Health trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
3 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
BRIGHT
BL1107

NCT07778888

Phase 2 · Not yet recruiting

Trial source and qualifications

BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

No eligible observations recorded in the inspected period.

    Start: Oct 2026 · estimated
    Primary completion: Feb 2027 · estimated
    Study completion: Feb 2027 · estimated

    2021202220232024202520262027202820292030
    Trulance
    plecanatide

    NCT07723924

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

    1 candidate observations · 1 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    Up to three verified eligible observations in the bounded history window.

    • status flip · Recorded 2026-10-03 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

    Start: 18 Aug 2026 · actual
    Primary completion: 18 Oct 2027 · estimated
    Study completion: 18 Oct 2027 · estimated

    2021202220232024202520262027202820292030
    Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
    Larsucosterol

    NCT07428538

    Phase 3 · Recruiting

    Trial source and qualifications

    Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

    2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    2 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 29 Jan 2026 · actual
      Primary completion: Nov 2027 · estimated
      Study completion: Feb 2028 · estimated

      2021202220232024202520262027202820292030

      Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

      3 selected of 3 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 0 actual primary completions, 0 untyped primary completions, 1 past estimates, 0 outside the horizon, 0 contradictory dates.

      04 / Therapeutic focus

      Where the activity is

      7

      active trials in Ophthalmology

      Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

      Active trials by primary therapeutic area

      • Ophthalmology7 trials
      • Dermatology5 trials
      • Immunology & Inflammation2 trials
      • Gastroenterology & Hepatology1 trials
      • Infectious Disease1 trials
      • Neurology1 trials
      • Psychiatry & Addiction1 trials
      • Unmapped5 trials
      • Healthy volunteers0 trials

      Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

      06 / Related companies

      All companies
      A

      AbbVie

      Shared indexed programme context · 1 selected asset

      A

      Amgen

      Shared indexed programme context · 1 selected asset

      A

      AstraZeneca

      Shared indexed programme context · 1 selected asset

      Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

      Sources, scope and methodology

      ClinicalTrials.gov lead-sponsor scope

      Enumerated controlled company group covers 485 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Bausch Health Companies Inc. · Bausch Health Americas, Inc. · Bausch & Lomb Incorporated. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion. The bare legacy Valeant identity is excluded pending exact legal-lineage evidence.

      ClinicalTrials.gov

      Attribution coverage

      485 distinct registry candidates produced 485 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 438 unverified, 2 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

      Indexed enrichment

      460 scoped records have indexed enrichment and 25 do not. Missing enrichment does not remove a trial from cohort counts.

      Scope observation

      The successful attribution check completed at 2026-10-30T22:59:14.409Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 9cd69e2d60ff4ac03505754dc654d8a1e5a5f4ca953ad44bc691aad7c567ecb8.

      Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

      Dated canonical-attribution snapshot: 485 mapped lead-sponsored clinical studies across all statuses. 460 have indexed enrichment, 25 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

      Keep following
      what matters.

      Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

      Build your watch

      Choose what to track in the watch builder.